

Acknowledgement and Consent for Disclosure of Potential Conflict(s) of Interest and a
Waiver under 18 U.S.C. §208(b)(3)

Ralph D'Agostino, Ph.D.

Committee: The Pediatric Subcommittee of the Oncologic Drugs Advisory Committee

Meeting Date: March 14, 2006

I acknowledge that contingent upon public disclosure of the financial interests listed below, related to the discussions of clinical trials of methotrexate and daunomycin to be conducted under the Best Pharmaceuticals for Children Act. Methotrexate is sponsored by Mayne Pharma USA, a Mayne Group Ltd. Cerubidine (daunorubicin, daunomycin) is sponsored by Bedford Laboratories, a division of Ben Venue Laboratories, Inc., a wholly owned subsidiary of Boehringer Ingelheim Corporation, the U.S. affiliate of Boehringer Ingelheim GmbH, I am eligible to receive a waiver under 18 U.S.C. §208(b)(3).

Type of Interest	Nature	Magnitude
Unrelated Consulting	Two Competitors	From \$10,001 to \$50,000 per year per firm
Advisory Board (Unrelated)	Two Competitors	Less than \$10,001 per year
Advisory Board (Unrelated)	Competitor	From \$10,001 to \$50,000 per year

I hereby request that FDA make this information publicly available on my behalf. I understand that without public disclosure of these interests the waiver is not valid.

//S//
Signature of SGE

2/9/06
Date